![Jean-Louis Escary](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Career history of Jean-Louis Escary
Former positions of Jean-Louis Escary
Companies | Position | Start | End |
---|---|---|---|
POLTREG S.A. | Corporate Officer/Principal | - | 2024-02-20 |
GenOdyssee SA
![]() GenOdyssee SA Miscellaneous Commercial ServicesCommercial Services GenOdyssee is a drug discovery company using a unique, IP-protected approach to discovery of superior protein products. GenOdyssee discovers natural variants of proteins with higher efficacy and safety than marketed versions of the same therapeutic proteins. This approach is ideal for discovery of 'next generation' protein products for already developed blockbuster markets. The company has a proprietary genomic DNA databank representative of the human population, which is screened for natural genetic variants of therapeutic proteins with superior properties. This approach to drug discovery is based on the idea that natural evolution may have lead to the generation in the current population of unpredictable mutations that would confer superior therapeutic status to known human therapeutic proteins. | Chairman | 1999-09-30 | 2011-05-10 |
Founder | 2009-12-17 | 2011-05-10 | |
President | 1999-09-30 | 2011-05-10 |
Training of Jean-Louis Escary
Statistics
International
France | 3 |
Poland | 2 |
Operational
Chairman | 1 |
Founder | 1 |
President | 1 |
Sectoral
Commercial Services | 2 |
Consumer Services | 2 |
Health Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
POLTREG S.A. | Health Services |
Private companies | 2 |
---|---|
GenOdyssee SA
![]() GenOdyssee SA Miscellaneous Commercial ServicesCommercial Services GenOdyssee is a drug discovery company using a unique, IP-protected approach to discovery of superior protein products. GenOdyssee discovers natural variants of proteins with higher efficacy and safety than marketed versions of the same therapeutic proteins. This approach is ideal for discovery of 'next generation' protein products for already developed blockbuster markets. The company has a proprietary genomic DNA databank representative of the human population, which is screened for natural genetic variants of therapeutic proteins with superior properties. This approach to drug discovery is based on the idea that natural evolution may have lead to the generation in the current population of unpredictable mutations that would confer superior therapeutic status to known human therapeutic proteins. | Commercial Services |
Université Pierre et Marie Curie | Consumer Services |
- Stock Market
- Insiders
- Jean-Louis Escary
- Experience